• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲状旁腺激素介导的高钙血症，经多次唑来膦酸输注后骨矿物质密度显著恢复

Parathyroid Hormone-Mediated Hypercalcemia With Remarkable Bone Mineral Density Recovery After Multiple Zoledronic Acid Infusions.

作者信息

Kpughur-Tule Meumbur P, Hubers Carly M, Renzu Mahvish, Conway Kendall, Satei Alexander M, Taha Wael

机构信息

Internal Medicine, Trinity Health Oakland/Wayne State University, Pontiac, USA.

Internal Medicine, Wayne State University School of Medicine, Detroit, USA.

出版信息

Cureus. 2024 Nov 11;16(11):e73435. doi: 10.7759/cureus.73435. eCollection 2024 Nov.

DOI:10.7759/cureus.73435
PMID:39669861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11634556/
Abstract

This case report describes a remarkable improvement in bone mineral density (BMD) in a 95-year-old female with parathyroid hormone (PTH)-mediated hypercalcemia following treatment with zoledronic acid. Despite her complex medical history, including chronic kidney disease (CKD) and osteoporosis, the patient experienced a significant increase in bone density, particularly in the left femoral neck, while maintaining stable renal function. This case highlights the efficacy and safety of zoledronic acid in elderly patients with osteoporosis and hypercalcemia, emphasizing the importance of careful monitoring to prevent renal complications. These findings offer valuable insights into the use of bisphosphonates in older populations with additional comorbidities.

摘要

本病例报告描述了一名95岁患有甲状旁腺激素（PTH）介导的高钙血症的女性患者，在接受唑来膦酸治疗后骨矿物质密度（BMD）有显著改善。尽管该患者有复杂的病史，包括慢性肾脏病（CKD）和骨质疏松症，但她的骨密度显著增加，尤其是左股骨颈，同时肾功能保持稳定。本病例突出了唑来膦酸在老年骨质疏松症和高钙血症患者中的疗效和安全性，强调了仔细监测以预防肾脏并发症的重要性。这些发现为在有其他合并症的老年人群中使用双膦酸盐提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/3e7de291f146/cureus-0016-00000073435-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/e1a9257745d6/cureus-0016-00000073435-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/f2a560b49f33/cureus-0016-00000073435-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/b76e88f7006b/cureus-0016-00000073435-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/318f18c46ca6/cureus-0016-00000073435-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/3e7de291f146/cureus-0016-00000073435-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/e1a9257745d6/cureus-0016-00000073435-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/f2a560b49f33/cureus-0016-00000073435-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/b76e88f7006b/cureus-0016-00000073435-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/318f18c46ca6/cureus-0016-00000073435-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6132/11634556/3e7de291f146/cureus-0016-00000073435-i05.jpg

相似文献

1
Parathyroid Hormone-Mediated Hypercalcemia With Remarkable Bone Mineral Density Recovery After Multiple Zoledronic Acid Infusions.甲状旁腺激素介导的高钙血症，经多次唑来膦酸输注后骨矿物质密度显著恢复
Cureus. 2024 Nov 11;16(11):e73435. doi: 10.7759/cureus.73435. eCollection 2024 Nov.
2
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.唑来膦酸可预防肝移植后的骨质流失：一项随机、双盲、安慰剂对照试验。
Ann Intern Med. 2006 Feb 21;144(4):239-48. doi: 10.7326/0003-4819-144-4-200602210-00005.
3
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.甲状旁腺激素与双膦酸盐治疗骨质疏松症的骨密度：随机对照试验的荟萃分析。
PLoS One. 2011;6(10):e26267. doi: 10.1371/journal.pone.0026267. Epub 2011 Oct 12.
4
Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study.模拟绝经早期骨密度保存对长期骨折风险的影响：一项可行性研究。
Osteoporos Int. 2021 Jul;32(7):1313-1320. doi: 10.1007/s00198-021-05826-5. Epub 2021 Jan 12.
5
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.唑来膦酸静脉给药联合特立帕肽[rhPTH(1-34)]皮下注射治疗绝经后骨质疏松症的效果。
J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.
6
Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.基线CTX水平升高预示唑来膦酸在中国骨质疏松症患者中增强腰椎骨密度的治疗效果更佳。
Osteoporos Int. 2025 Apr;36(4):707-714. doi: 10.1007/s00198-025-07448-7. Epub 2025 Mar 4.
7
Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.唑来膦酸对成骨不全成年患者的急性和长期影响。一项为期五年随访的西班牙观察性研究。
Endocrinol Diabetes Nutr (Engl Ed). 2019 Feb;66(2):108-116. doi: 10.1016/j.endinu.2018.05.015. Epub 2018 Aug 1.
8
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病（未透析）患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
9
A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study.绝经后妇女甲状旁腺激素相关蛋白（1-36）与甲状旁腺激素（1-34）对骨转换标志物和骨密度的比较：PrOP 研究。
J Bone Miner Res. 2013 Nov;28(11):2266-76. doi: 10.1002/jbmr.1978.
10
Treatment for osteoporosis in people with ß-thalassaemia.β地中海贫血患者骨质疏松症的治疗
Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2.

本文引用的文献

1
Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature.唑来膦酸输注治疗地舒单抗治疗后长期不良反应的经验教训：1 例病例报告及文献复习。
J Med Case Rep. 2022 Dec 16;16(1):473. doi: 10.1186/s13256-022-03695-y.
2
The Mechanism of Bone Remodeling After Bone Aging.骨老化后骨重建的机制。
Clin Interv Aging. 2022 Apr 5;17:405-415. doi: 10.2147/CIA.S349604. eCollection 2022.
3
Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management.
原发性甲状旁腺功能亢进症：诊断与药物治疗的叙述性综述
J Clin Med. 2021 Apr 9;10(8):1604. doi: 10.3390/jcm10081604.
4
Bisphosphonate therapy in CKD: the current state of affairs.慢性肾脏病中的双膦酸盐治疗：现状。
Curr Opin Nephrol Hypertens. 2020 Mar;29(2):221-226. doi: 10.1097/MNH.0000000000000585.
5
Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.慢性肾脏病中的双膦酸盐；平衡对骨骼和软组织的潜在益处与不良反应
Clin J Am Soc Nephrol. 2009 Jan;4(1):221-33. doi: 10.2215/CJN.02550508. Epub 2008 Nov 5.
6
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.每年一次唑来膦酸用于治疗绝经后骨质疏松症。
N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312.